The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
Open accessAbstract
Importance: Randomized clinical trials have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause significant weight loss and reduce cardiovascular events in patients with type 2 diabetes (T2D). Black patients have a disproportionate burden of obesity and cardiovascular disease and have a higher rate of cardiovascular-related mortality. Racial and ethnic disparities in health outcomes are largely attributable to the pervasiveness of structural racism, and patients who are marginalized by racism have less access to novel therapeutics. Objectives: To evaluate GLP-1 RA uptake among a commercially insured population of patients with T2D; identify associations of race, ethnicity, sex, and socioeconomic status with GLP-1 RA use; and specifically examine its use among the subgroup of patients with atherosclerotic cardiovascular disease (ASCVD) because of the known benefit of GLP-1 RA use for this population. Design Setting and Participants: This was a retrospective cohort analysis using data from OptumInsight Clinformatics Data Mart of commercially insured adult patients with T2D (with or without ASCVD) in the US. Data from October 1, 2015, to June 31, 2019, were included, and the analyses were performed in July 2020. We estimated multivariable logistic regression models to identify the association of race, ethnicity, sex, and socioeconomic status with GLP-1 RA use. Main Outcome and Measure: A prescription for a GLP-1 RA. Results: Of the 1 180 260 patients with T2D (median [IQR] age, 69 [59-76] years; 50.3% female; 57.7% White), 90 934 (7.7%) were treated with GLP-1 RA during the study period. From 2015 to 2019, the percentage of T2D patients treated with an GLP-1 RA increased from 3.2% to 10.7%. Among patients with T2D and ASCVD, use also increased but remained low (2.8%-9.4%). In multivariable analyses, lower rates of GLP-1 RA use were found among Asian (aOR, 0.59; 95% CI, 0.56-0.62), Black (adjusted odds ratio [aOR] 0.81; 95% CI, 0.79-0.83), and Hispanic (aOR, 0.91; 95% CI, 0.88-0.93) patients with T2D. Female sex (aOR, 1.22; 95% CI, 1.20-1.24) and higher zip code-linked median household incomes (>$100 000 [OR, 1.13; 95% CI, 1.11-1.16] and $50 000-$99 999 [OR, 1.07; 95% CI, 1.05-1.09] vs <$50 000) were associated with higher GLP-1 RA use. These results were similar to those found among patients with ASCVD. Conclusions and Relevance: In this cohort study of US patients with T2D, GLP-1 RA use increased, but remained low overall for treatment of T2D, particularly among patients with ASCVD who are likely to derive the most benefit. Asian, Black, and Hispanic patients and those with low income were less likely to receive treatment with a GLP-1 RA. Strategies to lower barriers to GLP-1 RA use, such as lower cost, are needed to prevent the widening of well-documented inequities in cardiovascular disease outcomes in the US.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a study of ~1.2 million commercially insured U.S. individuals with diabetes from 2015 to 2019, lower GLP‐1 use was seen among Asian, Black, and Hispanic, compared with White, individuals and among those living in lower versus higher income households [237].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [237]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One study demonstrated that of those medically eligible for this treatment, Asian, Black, Hispanic, and low-income patients are less likely to be treated with a GLP-1RAs.38”
From The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with our findings, other studies have demonstrated low rates of SGLT2i and GLP1ra medication use (11.2% and 8%, respectively), even among patients at high risk of cardiovascular disease.12–16,32”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have also broadly shown racial and ethnic differences in SGLT2i and GLP1ra prescriptions with Black, Hispanic/Latinx, and Asian groups receiving these medications at lower rates than White individuals.14–17”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous research has highlighted a pattern of treatment disparities that is consistent across various data sources [12–17].”
From Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Compounding this significant underuse, Black, Hispanic/Latinx, and Asian individuals receive fewer prescriptions for these medications compared to White individuals.14–17”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Although data on SGLT2i and GLP-1RA disparities in older Medicare patients with type 2 diabetes and comorbid HF, ASCVD and CKD are lacking, our findings generally align with existing literature on the diffusion of newer glucose-lowering therapies and racial and ethnic disparities [11–13, 16, 29].”
In the citing paper
“In a study of ∼1.2 million commercially insured U.S. individuals with diabetes from 2015 to 2019, lower GLP-1 use was seen among Asian, Black, and Hispanic, compared with White, individuals and among those living in lower versus higher income households [229].”
In the citing paper
“In a study of ∼1.2 million commercially insured U.S. individuals with diabetes from 2015 to 2019, lower GLP-1 use was seen among Asian, Black, and Hispanic, compared with White, individuals and among those living in lower versus higher income households [237].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Comorbidity measures for use with administrative data.
Elixhauser, A., Steiner, C., Harris, D. R., & Coffey, R. M. (1998) · Medical Care · doi:10.1097/00005650-199801000-00004 · Cited by 9,921
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Capps, L. (2003) · JAMA · doi:10.1001/jama.290.18.2487-b · Cited by 4,558
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Levels of racism: a theoretic framework and a gardener's tale
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.8.1212 · Cited by 2,626
How Structural Racism Works — Racist Policies as a Root Cause of U.S. Racial Health Inequities
Bailey, Z. D., Feldman, J. M., & Bassett, M. T. (2021) · New England Journal of Medicine · doi:10.1056/nejmms2025396 · Cited by 1,598
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Research works printed but not linked: 1
- Institute of Medicine, 2003, Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care
Cited by
Sorted by citations
Items 201–289 of 289
Jackson, N. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118429 · Cited by 1
Tekengne, B. O. T., Eke, C. I., Cumaaran, C., Ozigbo, A. A., Okoyeuzu, C., Okhagbuzo, I. M., Sadiq-Onilenla, R. A., & Okobi, O. E. (2025) · Cureus · doi:10.7759/cureus.91722 · Cited by 1
Kamoun, C., Huerta‐Saenz, L., Koren, D., Majidi, S., Mehta, S., Nokoff, N., Tremblay, E. S., Harris, R. M., Henry, R. K., Marks, B. E., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000548527 · Cited by 1
Akpan, N., Zhou, B., Rasu, R. S., & Sambamoorthi, U. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.1.14 · Cited by 2
Chuang, S., Khetpal, V., Lu, F. Q., & Wu, W. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103304 · Cited by 1
GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023
Chu, P. Y., Kelly, A., Hennessy, S., Vajravelu, M. E., Huang, J., & Amaral, S. G. (2026) · PEDIATRICS · doi:10.1542/peds.2025-071971 · Cited by 2
Characteristics of Youth Treated With GLP-1RAs at an Integrated Weight Management Clinic
Gregory, E. F., Shah, R. D., Michel, J. J., Huballah, Z. H., Frederick, N. A., Gunturi, D., & Edmondson, E. K. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074094 · Cited by 1
Baidya, J., Dalton, J., Baek, G., Fano, A. N., Oris, R. J., Huang, R., Herczeg, C. K., Olson, J., Ng, M., Green, W. A., et al. (2026) · European Spine Journal · doi:10.1007/s00586-026-09849-6 · Cited by 2
Collaborators, G. U. H. D., Mouhanna, F., Kahn, E., Schmidt, C. A., McHugh, T. A., Baumann, M. M., Kelly, Y. O., Motte‐Kerr, W. L., Cogen, R. M., Dai, X., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04795-y · Cited by 1
German, J., Huang, W. A., Brucker, A., Daniel, K., Halpern, D. J., Bhavsar, N. A., Hinz, E. M., Shannon, R., Pignone, M. P., Crowley, M. J., et al. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005546 · Cited by 1
Geographic variation in eligibility and uptake of GLP-1 receptor agonists for obesity in US adults
Jian, X., Kang, B., Zhang, B., Tang, H., Xu, H., Chen, Y., & Lu, Y. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101653 · Cited by 1
Incretin therapies, nutrition and food insecurity in the UK
Spreckley, M., Ruggiero, C. F., & Brown, A. C. (2026) · Nature Medicine · doi:10.1038/s41591-026-04426-2 · Cited by 1
Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024
Lux, T. S., Lee, D., Phillips, J. M., Facelli, J. C., Malone, D. C., Wahl, M., Reddy, D., Sakaguchi, F. H., Gouripeddi, R., Millar, A. S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71013 · Cited by 1
Seeing Beyond GLP‐1: A Systems View of Sustainable Obesity Care
Mui, Y., Winkler, M. R., Ramsing, B., Palmer, A., & Altema-Johnson, D. (2026) · Journal of human nutrition and dietetics (Print) · doi:10.1111/jhn.70300 · Cited by 1
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide
Kozato, A., Patel, S. S., Orandi, B. J., Massie, A. M., Mańkowski, M., Fielding, C. R., Segev, D. L., Parikh, M., & Chhabra, K. R. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13147-z · Cited by 1
Glucagon-like peptide-1 receptor agonists in dermatology: ethical considerations
Deitelzweig, C., Rahim, F. G., & Stoff, B. K. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.016 · Cited by 1
Glucagon-like Peptide 1 Receptor Agonist Use in Hospital: A Multicentre Observational Study
Ray, P., Moggridge, J. A., Weisman, A., Tadrous, M., Drucker, D. J., Perkins, B. A., & FRALICK, M. (2024) · Canadian Journal of Diabetes · doi:10.1101/2024.08.01.24311352 · Cited by 1
Arena, R. A., & Pronk, N. P. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102966 · Cited by 1
Obesity and Cardiovascular-Kidney-Metabolic Health
Ghanta, S. N., Lessey, C., Makwana, B., Ganatra, S., & Dani, S. S. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.009 · Cited by 1
Liaw, W. R., Adepoju, O. E., Luo, J., Glasheen, B., King, B. T., Kakadiaris, I. A., PREWITT, T. G., Womack, P., Dobbins, J., Madani, M., et al. (2025) · Population Health Management · doi:10.1089/pop.2025.0054 · Cited by 1
Self-citationHussien, A., Alkharasani, A. M., Alaboudi, Z. A., -, S. A. S. A., Suliman, T. A., Alanazi, A., Ezzi, M. I., Almajid, G. J., Almutleeg, Z. H., & Msawa, M. A. (2025) · Cureus · doi:10.7759/cureus.85017 · Cited by 1
TIRZEPATIDA E ESTÉTICA CORPORAL: POTENCIAL TERAPEUTICO NO EMAGRECIMENTO E SEUS EFEITOS ADVERSOS
de Gois, N. P., Mora, R., de Mendonça, G. J. G., Clavijo, B., do Nascimento, S. B., Carneiro, F. F., Scalabrini, E. B., Shibata, C., & Pessôa, F. S. (2025) · Revista Contemporânea · doi:10.56083/rcv5n7-144 · Cited by 4
Bernstein, E. Y., Moreno, J. O., & Edelman, E. J. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08565-x · Cited by 1
Efficacy of Tirzepatide for Weight Loss in China: Implications for the Global Obesity Epidemic.
Qian, F., & Hu, F. B. (2024) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2024.7928 · Cited by 1
Boateng, S., Ameyaw, P. A., Issaka, Y., Al‐Ajlouni, Y. A., & Njei, B. M. (2025) · Research Square · doi:10.21203/rs.3.rs-6926160/v1 · Cited by 1
Reframing the need for exercise therapy in the clinical management of people living with obesity
Grannell, A. (2022) · Clinical Obesity · doi:10.1111/cob.12554 · Cited by 1
Bancks, M. P. (2023) · Diabetes Care · doi:10.2337/dci23-0023
Osude, N., & Pagidipati, N. J. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.11.003
Racial and Ethnic Differences in Obesity Treatment in the Veterans Affairs Healthcare SystemPreprint
Tisdale, R. L., Beyene, T. J., Tang, W., Heidenreich, P. A., Asch, S. M., & Yong, C. M. (2024) · medRxiv · doi:10.1101/2024.02.02.24302244
Hoog, M. M., Maldonado, J. M., Dixon, R. W., Halpern, R., Buysman, E. K., Gremel, G. W., Huang, A., & Кониг, М. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01542-5
Increasing pharmacoequity for people with cirrhosis
Hundt, M. A., & Kardashian, A. A. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000203
Barrett, A., Boye, K. S., García‐Pérez, L., Giorgino, F., Guerci, B., Füchtenbusch, M., Yu, M., Sapin, H., Dib, A., Heitmann, E., et al. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2367919
Influence of Patient Gender and Race on Obstructive Sleep Apnea in Perioperative Medicine
Johnson, T. J. (2024) · Anesthesiology Clinics · doi:10.1016/j.anclin.2024.07.003
Auerbach, N., Liu, V. N., Huang, D. R., Clift, A. K., Al-Ammouri, M., & El-Osta, A. A. R. (2024) · Research Square · doi:10.21203/rs.3.rs-5689779/v1
Kim, Y. Y., Kim, J. H., & Shin, J. (2024) · Precision and Future Medicine · doi:10.23838/pfm.2024.00170 · Cited by 1
Access to GLP-1s: Where Do Employers Fit in?
Imboden, M. T. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251335507a
Chen, A. S., Brunetto, W. L., Canavan, M., Lipska, K. J., Richey, E. A., Wilson, M. S., Zarro, J., & Ross, J. S. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09691-4
The metabolic advantage of being young and male in obesity treatment outcomes in mice
Dirnberger, A. S., Rodríguez, E. Y. A., Rodrı́guez, E. C. A., Hanson, J. O. D., Sun, Y., Delima, D., Bykov, B. F., da Silva, A. F., Kraljević, M., Marins, F. A. S., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00065-2
Lan, N., Liang, X., Li, Y., Han, L., Ou, H., Luo, Z., Li, J., Lin, Y., & Zhang, X. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5364609
Lavenburg, L.-M. U., Mosslemi, M., Han, Z., Weltman, M. R., Alghwiri, A. A., Fischer, G. S., Rollman, B. L., Yabes, J. G., & Jhamb, M. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0046
Response to Letter to the Editor
(2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100215
Improving nutritional assessment in GLP-1RA therapy: Beyond self-reports to equitable interventions
Aphale, P., Shekhar, H., & Dokania, S. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100213
Olar, P., Gray, C. S., Bakel, T. V., Benjamin, J., & Fralick, M. (2025) · medRxiv · doi:10.1101/2025.10.27.25338651
Playter, K. P., Chen, Y.-H., Grant, A. R., Chen, Y., Travers, H. I., Hollenbeck, B. L., Nin, D. Z., Niu, R., Talmo, C. T., Chang, D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7490872/v1
Kasaie, P., Zhao, Y., Humes, E., Gerace, L., Reid, K. A., Lesko, C. R., Kurgansky, K. E., Koethe, J. R., Rebeiro, P. F., Bourgi, K., et al. (2025) · medRxiv · doi:10.1101/2025.11.05.25339607
D’Oro, A., D’Costa, Z. U., Tang, J., Min, S., Jackson, L. R., & Essien, U. R. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101361
Self-citationCharacterizing Sleep-disordered Breathing by Race and Ethnicity
Rodriguez, A. J., Bubu, O. M., & Osorio, R. S. (2025) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2025.10.014
Yamaoka, T., Sugiyama, T., Nishioka, D., Kondo, N., & Tamiya, N. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70213
Srivastava, G., Madhar, A., & Chen, Y. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702251380864
Association of Patient Cost-Sharing With Adherence to GLP-1a and Adverse Health Outcomes
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., E. Grams, M., Wright, D. R., Hsing-Chun Wang, V., Rajan, A., Butt, E., Shin, J.-I., et al. (2025) · Figshare · doi:10.60929/nyulangone.28995647
Ahmed, F., Borghol, A., Grady, M., Rivera, L., Meyers, S., & Olet, S. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2606551
Khela, H. S., Kishan, A., Manriquez, A. H., Kirby, L., Chisango, Z. M., Carayannopoulos, N. L., Singh, M., Cottrill, E. J., Avedian, R. S., Kleck, C. J., et al. (2026) · Spine Open · doi:10.1097/bn9.0000000000000051
Poor Access to Anti-Obesity Medications in Metabolic Dysfunction-Associated Steatotic Liver Disease
Hurr, S., Giang, J., & Barritt, A. S. (2026) · North Carolina Medical Journal · doi:10.18043/001c.154980
Gupta, R., Sunner, S. S., & Lam, A. P. (2026) · Current Opinion in Physiology · doi:10.1016/j.cophys.2026.100930
Socioeconomic inequalities in cardiometabolic health among United States adults using NHANES data
Bagci, S., & Ozel, F. (2026) · Discover Public Health · doi:10.1186/s12982-026-01681-z
de Mestral, C., Khalatbari‐Soltani, S., Bodenmann, P., Henchoz, Y., & Avendano, M. (2026) · The Journal of Frailty & Aging · doi:10.1016/j.tjfa.2026.100134
Mallette, J. H., Speed, J. S., Lirette, S. T., Moore, D., & Clemmer, J. S. (2026) · Obesity · doi:10.1002/oby.70180
Fioretti, F., Petrie, M. C., Dickert, N. W., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5086
Rodriguez, M. E., Lavell, J., & Foreman, R. M. (2026) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000430
Characterizing Disparities in GLP-1 Receptor Agonist Use Among US Adults With and Without Diabetes
Elkin, J., Shadbolt, C., Schilling, C., Hii, M., Sumithran, P., Choong, P. F. M., & Dowsey, M. (2026) · Journal of general internal medicine · doi:10.1007/s11606-026-10506-3
Of Fasts and Feasts: Catholic Ethics and the Right Use of GLP-1 Agonists for Weight Loss
Starr, A. Y. A. (2026) · The Linacre Quarterly · doi:10.1177/00243639261450700
Breaking Barriers in Obesity Care — Scaling a Primary Care Weight Management Program Statewide
Ro, S., McCauley, J., Schaeffer, J., Gupta, S., & Fiscus, L. C. (2026) · NEJM Catalyst · doi:10.1056/cat.25.0345
Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid BlepharoplastyPreprint
Almeida, V. F. A., Ha, J., Duraes, F., Dantas, M., Hashem, A. M., Djohan, R. S., & Duraes, E. F. R. (2026) · Research Square · doi:10.21203/rs.3.rs-9665910/v1
“Yeah but …”: shifting our mindset around body weight in organizational research
Lemmon, G., Jensen, J. M., & Kuljanin, G. (2026) · Equality Diversity and Inclusion An International Journal · doi:10.1108/edi-08-2025-0575
The Role of GLP-1 Agonists in Weight Management: Barriers, Effectiveness, and Safety Perceptions
Silwal, P., Dilley, A., Adhikari, S., Lusk, J. L., & McFadden, B. R. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-026-01243-y
Shoulder Arthroplasty Outcomes Using Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review
Nguyen, K. M. K. P., Lee, V., Jones, E. N., Doroodchi, R., Avant, J. S., & Ponce, B. A. (2026) · Journal of Orthopaedic Experience & Innovation · doi:10.60118/001c.155814
Moka, A. O., Nwachi, D., Igboanude, C. H., Adelaja, A. T., Olabode, M. D., & Okpaluba, O. C. (2026) · Research Square · doi:10.21203/rs.3.rs-9795190/v1
McCann, C. J., Clement, N., Murray, A. D., Kearney, R., Madigan, S. M., Gee, C. W., Walmsley, P., Morrison, S. R., Chopra, S., & Hall, A. J. (2026) · British Journal of Sports Medicine · doi:10.1136/bjsports-2025-111225
Ibrahim, N., Ibrahim, H. D., Banda, E. L., & Boakye, M. D. S. (2026) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-026-03080-1
Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series
Nguyen, A.-T., & Binkley, J. L. (2026) · Case Reports in Pediatrics · doi:10.1155/crpe/5562574
Sheth, M. S., Jeong, I. J., Chu, A., Basque, S. R., Fang, J., McNaughton, C. D., Ko, D. T., Abdel-Qadir, H. M., Lee, D. S., & Udell, J. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.06.027
Sunder, V., Garrow, J., Iterson, E. H. V., Tobb, K., Opet, N., Tsai, S. A., Asamoah, E., Garg, P., Singh, A., Namutebi, J. H., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1838136
Huang, X., Zhang, X., Yu, X., Wang, T., She, Y., Wang, M., Yang, Y., Liu, Y., Feng, L., Hao, X., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02439-w
Glucagon-Like Peptide-1 Receptor Agonists Use Among Reproductive-Aged Women with Type 2 Diabetes
Bailey, S. C., Cameron, N. A., Batio, S., Wismer, G. A., Wolf, M. S., Wallia, A., Schauer, J. M., Gemkow, J. W., Eggleston, A., Tenfelde, S., et al. (2026) · Journal of Women s Health · doi:10.1177/15409996261478007
Early combination therapy in type 2 diabetes: Rethinking initial treatment strategies
Janež, A., Smid, T., Rizzo, M., & Tankova, T. I. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109392
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Wang, J., Pederson, A. M., Flanders, M. D., Choi, M., Buto, P. T., Sims, K. D., Chen, R., Couch, E., Gilsanz, P., Hayes, K. N., et al. (2026) · medRxiv · doi:10.64898/2026.09.04.26362304
Salmela, J., Svärd, A. C., Roos, E., Joki, A., Kouvonen, A. M., & Lallukka, T. M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02213-0
Huang, W., Kotecha, P., Kimmel, S. E., Segal, R., Gonzalvo, J. D., Pecoski, A. M., Wright, D. R., Bian, J., Smith, S. M., & Guo, J. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71299
Global barriers to GLP-1 receptor agonist treatment in women: access, safety, and equity
Meek, C. L., Anjana, R. M., Chandiwana, N. C., Chow, E. W. K., Franco, D. R., Halpern, B., Lamptey, R., Lingvay, I., Ma, R. C. W., Mohan, V., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(26)00228-1
Wang, Y., Liu, Z., Wang, S., Lv, C., El-Seedi, H. R., Khalifa, S. A. M., & Wang, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70351
Chu, A., Olsen, B., Choi, J., Sarwal, A., Sakaguchi, F., Akramimoghadam, F., Jacobs, J. A., Reddy, D., Bhatt, N., Iyalomhe, O. E., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02431-y
Qureshi, S., Sajid, M., Khan, H. R., Greene, S. J., Fudim, M., McCann, G. P., Squire, I. B., Waqas, S. A., Khan, M. S., Lawson, C., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.10.001
Functional Implications of GLP-1RA Use Beyond Obesity in Aging Adults
Mascone, S. E., Prior, S. J., & Addison, O. R. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00467-0
Pavuluri, C., Rao, A., Sholle, E., Ma, X., Gullapelli, R., Nasir, K., Sadhu, A., Avenatti, E., & Kashyap, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10720063/v1
Madero, M. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01136-3
Rivera, N., Bradley, T., Crowell, K., Goodwin, C. R., & Erickson, M. M. (2026) · The Spine Journal · doi:10.1016/j.spinee.2026.10.020
GLP-1 RA Prescribing in Patients With Type 2 Diabetes and Cancer
Hu, X., Jiang, C., Han, X., Zhang, L., Li, P., Pasquel, F. J., Meisel, J. L., Vo, J. B., Varghese, J. S., Shao, H., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.40781
Qeadan, F., Madden, E. F., & Burge, M. R. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2758041
Metadata
- Authors
- Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., Groeneveld, P. W., & Adusumalli, S.
- Affiliations
- Leonard Davis Institute of Health Economics (US)
- University of Pennsylvania (US)
- University of Pittsburgh (US)
- VA Pittsburgh Healthcare System (US)
- Philadelphia VA Medical Center (US)
- Corresponding author
- Eberly, Lauren A.
- ORCID
- Venue
- JAMA Health Forum
- Publisher
- American Medical Association (AMA)
- Published
- 2021-12-17
- Volume
- 2
- Issue
- 12
- Pages
- e214182
- ISSN
- 2689-0186 (ISSN-L)
- PMC
- PMC8796881
- OpenAlex
- W4200521668
- Cited by
- 288
- References
- 39
- Citations by year
- 2026: 60 · 2025: 114 · 2024: 71 · 2023: 31 · 2022: 11
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- JAMA Health Forum (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K23HL153772)
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK120956)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Health › Health disparities and outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, racial and ethnic disparities, socioeconomic status, atherosclerotic cardiovascular disease, Black patients, Asian patients, prescription drug use, structural racism, commercially insured patients, sex differences, treatment disparities, cardiovascular risk reduction, weight loss, United States
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Ethnicity, Female, Humans, Male, Retrospective Studies, Socioeconomic Factors, Cohort Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
